If you notice text formatting issues, please update your browser to view the website correctly
.
See More
If you notice text formatting issues, please update your browser to view the website correctly
.
See MoreIf you notice text formatting issues, please update your browser to view the website correctly
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Expression of TNF by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated for 6 hours with PMA (Sigma, Cat. #P-8139) and calcium ionophore A23187 (Sigma, Cat. #C-9275) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554715). The PBMC were stained with PE-Cy™5 Mouse Anti-Human CD3 (Cat. No. 555334), fixed, permeabilized, and subsequently stained with 0.25 µg of FITC Mouse Anti-Human TNF (Cat. No. 554512/562082/552889, left panel). To demonstrate specificity of staining, the binding of FITC Mouse Anti-Human TNF was blocked by the preincubation of the fluorochrome-conjugated antibody with recombinant human TNF (5 µg, Cat. No. 554618; middle panel), and by preincubation of the fixed/permeabilized cells with Purified Mouse Anti-Human TNF (5 µg, Cat. No. 554510; right panel) prior to staining with the FITC Mouse Anti-Human TNF. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.
Expression of TNF by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated for 6 hours with PMA (Sigma, Cat. #P-8139) and calcium ionophore A23187 (Sigma, Cat. #C-9275) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554715). The PBMC were stained with PE-Cy™5 Mouse Anti-Human CD3 (Cat. No. 555334), fixed, permeabilized, and subsequently stained with 0.25 µg of FITC Mouse Anti-Human TNF (Cat. No. 554512/562082/552889, left panel). To demonstrate specificity of staining, the binding of FITC Mouse Anti-Human TNF was blocked by the preincubation of the fluorochrome-conjugated antibody with recombinant human TNF (5 µg, Cat. No. 554618; middle panel), and by preincubation of the fixed/permeabilized cells with Purified Mouse Anti-Human TNF (5 µg, Cat. No. 554510; right panel) prior to staining with the FITC Mouse Anti-Human TNF. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.
Expression of TNF by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated for 6 hours with PMA (Sigma, Cat. #P-8139) and calcium ionophore A23187 (Sigma, Cat. #C-9275) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554715). The PBMC were stained with PE-Cy™5 Mouse Anti-Human CD3 (Cat. No. 555334), fixed, permeabilized, and subsequently stained with 0.25 µg of FITC Mouse Anti-Human TNF (Cat. No. 554512/562082/552889, left panel). To demonstrate specificity of staining, the binding of FITC Mouse Anti-Human TNF was blocked by the preincubation of the fluorochrome-conjugated antibody with recombinant human TNF (5 µg, Cat. No. 554618; middle panel), and by preincubation of the fixed/permeabilized cells with Purified Mouse Anti-Human TNF (5 µg, Cat. No. 554510; right panel) prior to staining with the FITC Mouse Anti-Human TNF. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.
Expression of TNF by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated for 6 hours with PMA (Sigma, Cat. #P-8139) and calcium ionophore A23187 (Sigma, Cat. #C-9275) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554715). The PBMC were stained with PE-Cy™5 Mouse Anti-Human CD3 (Cat. No. 555334), fixed, permeabilized, and subsequently stained with 0.25 µg of FITC Mouse Anti-Human TNF (Cat. No. 554512/562082/552889, left panel). To demonstrate specificity of staining, the binding of FITC Mouse Anti-Human TNF was blocked by the preincubation of the fluorochrome-conjugated antibody with recombinant human TNF (5 µg, Cat. No. 554618; middle panel), and by preincubation of the fixed/permeabilized cells with Purified Mouse Anti-Human TNF (5 µg, Cat. No. 554510; right panel) prior to staining with the FITC Mouse Anti-Human TNF. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.
Expression of TNF by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated for 6 hours with PMA (Sigma, Cat. #P-8139) and calcium ionophore A23187 (Sigma, Cat. #C-9275) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554715). The PBMC were stained with PE-Cy™5 Mouse Anti-Human CD3 (Cat. No. 555334), fixed, permeabilized, and subsequently stained with 0.25 µg of FITC Mouse Anti-Human TNF (Cat. No. 554512/562082/552889, left panel). To demonstrate specificity of staining, the binding of FITC Mouse Anti-Human TNF was blocked by the preincubation of the fluorochrome-conjugated antibody with recombinant human TNF (5 µg, Cat. No. 554618; middle panel), and by preincubation of the fixed/permeabilized cells with Purified Mouse Anti-Human TNF (5 µg, Cat. No. 554510; right panel) prior to staining with the FITC Mouse Anti-Human TNF. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.
Expression of TNF by stimulated human peripheral blood mononuclear cells (PBMC). Human PBMC were stimulated for 6 hours with PMA (Sigma, Cat. #P-8139) and calcium ionophore A23187 (Sigma, Cat. #C-9275) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554715). The PBMC were stained with PE-Cy™5 Mouse Anti-Human CD3 (Cat. No. 555334), fixed, permeabilized, and subsequently stained with 0.25 µg of FITC Mouse Anti-Human TNF (Cat. No. 554512/562082/552889, left panel). To demonstrate specificity of staining, the binding of FITC Mouse Anti-Human TNF was blocked by the preincubation of the fluorochrome-conjugated antibody with recombinant human TNF (5 µg, Cat. No. 554618; middle panel), and by preincubation of the fixed/permeabilized cells with Purified Mouse Anti-Human TNF (5 µg, Cat. No. 554510; right panel) prior to staining with the FITC Mouse Anti-Human TNF. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
The FITC-conjugated MAb11 antibody can be used for multicolor immunofluorescent staining and flow cytometric analyses to identify and enumerate TNF-producing cells within mixed cell populations (see figure). For optimal immunofluorescent staining with flow cytometric analysis, this anti-cytokine antibody should be titrated (≤ 0.5 µg mAb/million cells) For specific methodology, please visit the protocols section under "Cytokines (Intracellular Staining)" or "Intracellular Flow" at our website, http://www.bdbiosciences.com/us/s/resources.
A useful control for demonstrating specificity of staining is either of the following: 1) pre-block the conjugated MAb11 antibody with a molar excess of ligand (e.g., recombinant human TNF; Cat No. 554618) prior to staining, or 2) pre-block the fixed/ permeabilized cells with unlabelled MAb11 antibody (Cat. No. 554510) prior to staining. The staining technique and blocking controls are described in detail by C. Prussin and D. Metcalfe. A suitable mouse IgG1 isotype control for assessing the level of background staining on paraformaldehyde-fixed/saponin-permeabilized human cells is FITC-MOPC-21 (Cat. No. 554679); use at comparable concentrations to antibody of interest.
The MAb11 monoclonal antibody specifically binds to human tumor necrosis factor (TNF, also known as TNF-α) protein. TNF is an efficient juxtacrine, paracrine and endocrine mediator of inflammatory and immune functions. It regulates the growth and differentiation of a variety of cell types. TNF is cytotoxic for transformed cells when in conjunction with IFN-γ. It is secreted by activated monocytes/macrophages and other cells such as B cells, T cells and fibroblasts. The immunogen used to generate the MAb11 hybridoma was recombinant human TNF. The MAb11 antibody has been reported to crossreact with Rhesus Macaque TNF.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.